David R. Epstein, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold 370 shares of the company's Class A Common Stock. The shares were sold on February 3, 2025, at an average price of $53.31 ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...